© 2001 by Society
© 2001 by the Society forNeuro-Oncology
Prevalence estimates for primary brain tumors in the United States bybehavior and major histology groups
Division of Epidemiology and Biostatistics, School of Public Health,University of Illinois at Chicago, Chicago, IL 60612
2 Address correspondence and reprint requests to Faith G. Davis, Professor andDirector, Division of Epidemiology and Biostatistics, School of Public Health,University of Illinois at Chicago, 2121 West Taylor St., Chicago, IL 60612.
 |
Abstract |
|---|
Prevalence rates are used to supplement descriptions of disease and areunavailable for all primary brain tumors in the United States. Data from twopopulation-based tumor registries were obtained from the Central Brain TumorRegistry of the United States and used to compute age-specific incidence rates(1985-1994) and survival curves for further use in a statistical model toestimate prevalence rates. Prevalence rates were then used to estimate thenumber of individuals living with a brain tumor diagnosis in the U.S.population for the year 2000. The overall incidence rate in these regions is13.8 per 100,000 with 2-, 5-, and 10-year survival rates of 58%, 49%, and 38%,respectively. The prevalence rate for all primary brain tumors is 130.8 per100,000 with approximately 350,000 individuals estimated to be living withthis diagnosis in the United States in 2000. The prevalence rate for malignanttumors, 29.5 per 100,000, is similar to previous reports. The prevalence ratefor benign tumors, 97.5 per 100,000, is new. Unlike incidence data, theproportion (and expected number) of existing benign tumors (75%, 267,000) isconsiderably greater than that for malignant tumors (23%, 81,000), reflectingthe better prognosis of benign tumors diagnosed in individuals younger than 60years old. These data underscore the impact of primary brain tumors in theU.S. health care system and emphasize the need for quality-of-lifeconsiderations, particularly for those long-term survivors of benigntumors.
Received October 9, 2000; Accepted February 22, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. R. Porter, B. J. McCarthy, S. Freels, Y. Kim, and F. G. Davis Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology Neuro Oncology, February 8, 2010; (2010) nop066v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wiesner, S. A. Decker, J. D. Larson, K. Ericson, C. Forster, J. L. Gallardo, C. Long, Z. L. Demorest, E. A. Zamora, W. C. Low, et al. De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA Cancer Res., January 15, 2009; 69(2): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X.-x. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin, and J. S. Yu Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients Cancer Res., July 15, 2008; 68(14): 5955 - 5964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Schubart, M. B. Kinzie, and E. Farace Caring for the brain tumor patient: Family caregiver burden and unmet needs Neuro Oncology, February 1, 2008; 10(1): 61 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M. A. Tichomirowa, and A. Beckers High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4769 - 4775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Hussain, D. Yang, D. Suki, K. Aldape, E. Grimm, and A. B. Heimberger The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses Neuro Oncology, July 1, 2006; 8(3): 261 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Wheeler, A. Das, G. Liu, J. S. Yu, and K. L. Black Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination Clin. Cancer Res., August 15, 2004; 10(16): 5316 - 5326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Yu, G. Liu, H. Ying, W. H. Yong, K. L. Black, and C. J. Wheeler Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma Cancer Res., July 15, 2004; 64(14): 4973 - 4979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Wheeler, K. L. Black, G. Liu, H. Ying, J. S. Yu, W. Zhang, and P. K. Lee Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality J. Immunol., November 1, 2003; 171(9): 4927 - 4933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. S. Berger Epidemiology of primary brain tumors: Current concepts and review of theliterature Neuro Oncology, October 1, 2002; 4(4): 278 - 299. [Abstract] [PDF]
|
|